多重生物標記成像市場規模、佔有率和成長分析：按組件、成像技術、應用、最終用戶和地區分類—2026-2033年產業預測

2024 年全球多重生物標記成像市場價值為 4.8708 億美元，預計將從 2025 年的 5.3968 億美元成長到 2033 年的 12.2591 億美元，在預測期（2026-2033 年）內以 10.8% 的複合年成長率成長。

多重生物標記成像市場正經歷顯著的發展趨勢，這主要得益於先進技術的進步，這些技術能夠同時檢測單一組織切片中的多種蛋白質和核酸標靶。這項技術增強了研究和臨床診斷中的空間分析能力，有助於深入了解細胞異質性和複雜的訊號網路，從而強化精準腫瘤學和免疫療法。從早期的螢光多重檢測到如今的先進平台，多重檢測技術的演進簡化了工作流程，最大限度地減少了檢體消耗，並吸引了許多渴望檢驗生物標記的製藥公司的注意。監管機構要求提供全面的多重檢測數據以證明標靶在不同腫瘤微環境中的表達，這推動了伴隨診斷需求的成長，進而促進了市場擴張。因此，對自動化和分析領域的投資增加正在推動市場成長並創造商機。

全球多重生物標記成像市場的成長要素

高解析度成像技術（包括光學和質譜系統）的不斷進步，使得同時可視化多種生物標記成為可能，從而提高了靈敏度和空間精度。這項創新減少了對大量連續檢測的需求，簡化了實驗流程，並帶來了更深入的生物學見解。因此，研究人員和臨床醫生正擴大將多重影像技術納入標準臨床實踐。這種轉變推動了對高度適應性成像解決方案的需求，並透過產品創新和在各種治療和研究環境中更廣泛的臨床應用，刺激了市場成長，最終改變了生物標記分析和診斷的格局。

全球多重生物標記成像市場的限制因素

全球多重生物標記成像市場面臨嚴峻挑戰，這主要是由於許多研究機構和臨床檢查室，尤其是預算有限的機構，面臨資金限制。先進的多重影像系統初始成本高昂，加上持續的維護、軟體許可和專業培訓費用，構成了一道巨大的財務障礙。因此，潛在買家往往會推遲甚至放棄對先進系統的投資，轉而選擇更經濟實惠的傳統單靶點成像方法。這種成本敏感度限制了市場成長，迫使供應商專注於提高產品的價格可負擔性，以有效地擴展其全球基本客群。

全球多重生物標記成像市場趨勢

受人工智慧 (AI) 與先進成像技術融合的推動，全球多重生物標記成像市場正呈現上升趨勢。 AI 驅動的多重平台正在革新檢測方法的開發，實現跨多個標靶的快速模式識別，並最終簡化工作流程。機器學習演算法最佳化螢光染料的選擇，最大限度地減少低效環節，並加快新診斷方法的上市速度。雲端分析技術的日益普及促進了研究機構間的合作，並推動了標準化調查方法和資源的共用。這些技術的整合不僅提高了診斷的準確性，也增強了多重影像解決方案在全球醫療保健領域（包括藥物研發和精準醫療）的商業性吸引力。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球多重生物標記成像市場規模：按組件分類

• 裝置
  • 影像系統
  • 檢測裝置
• 試劑和耗材
• 軟體
• 服務

全球多重生物標記成像市場規模：按成像技術分類

• 螢光（IF）檢測
• 免疫組織化學（IHC）檢測
• 螢光原位雜合反應（FISH）
• 組織微陣列（TMA）偵測
• Toponome Imaging System（TIS）

全球多重生物標記成像市場規模：按應用領域分類

• 腫瘤學研究
• 藥物安全測試
• 遺傳性狀分析研究

全球多重生物標記成像市場規模：按最終用戶分類

• 製藥和生物技術公司
• 研究機構
• 臨床診斷檢測實驗室
• 政府和公共研究機構

全球多重生物標記成像市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• PerkinElmer Inc.
• Bio-Rad Laboratories Inc.
• Thermo Fisher Scientific Inc.
• US Biomax Inc.
• Abcam plc（now Abcam）
• Agilent Technologies Inc.
• Leica Biosystems（Danaher）
• Akoya Biosciences Inc.
• 10x Genomics Inc.
• Beckman Coulter（Danaher）
• BioView Ltd.
• Hamamatsu Photonics KK
• NanoString Technologies Inc.
• Ventana Medical Systems（Roche）
• Merck KGaA（Sigma-Aldrich）
• Cell Signaling Technology Inc.
• Fluidigm Corporation
• Indicell Biotech
• Phenoimager（formerly Vectra PerkinElmer）
• Synaptic Research LLC

結論與建議

Global Multiplex Biomarker Imaging Market size was valued at USD 487.08 Million in 2024 and is poised to grow from USD 539.68 Million in 2025 to USD 1225.91 Million by 2033, growing at a CAGR of 10.8% during the forecast period (2026-2033).

The multiplex biomarker imaging market is witnessing significant trends driven by advanced technologies that facilitate the simultaneous detection of multiple protein or nucleic acid targets within a single tissue section. This capability enriches spatial profiling for both research and clinical diagnostics, allowing insight into cellular heterogeneity and intricate signaling networks, thus enhancing precision oncology and immunotherapy initiatives. The evolution from early immunofluorescence multiplexes to cutting-edge platforms has streamlined workflows, minimized sample consumption, and captured the interest of pharmaceutical companies eager to validate biomarkers. The rising demand for companion diagnostics is propelling market expansion, as regulators push for comprehensive multiplex data to substantiate target expression in diverse tumor microenvironments. Consequently, increased investments in automation and analytics are fostering market growth and generating revenue opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiplex Biomarker Imaging market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiplex Biomarker Imaging Market Segments Analysis

Global multiplex biomarker imaging market is segmented by component, imaging technique, application, end user and region. Based on component, the market is segmented into instruments, reagents & consumables, software and services. Based on imaging technique, the market is segmented into immunofluorescence (IF) assay, immunohistochemistry (IHC) assay, fluorescent in situ hybridization (FISH), tissue microarray (TMA) assay and toponome imaging system (TIS). Based on application, the market is segmented into oncology studies, drug safety testing and genetic characterization studies. Based on end user, the market is segmented into pharmaceutical & biotechnology companies, research institutes, clinical diagnostic laboratories and government & public research bodies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiplex Biomarker Imaging Market

The ongoing advancement of high-resolution imaging technologies, encompassing optical and mass spectrometry systems, facilitates the simultaneous visualization of multiple biomarkers, enhancing sensitivity and spatial precision. This innovation diminishes the necessity for numerous sequential assays, streamlining experimental processes and offering deeper biological insights. As a result, researchers and clinicians are increasingly integrating multiplex imaging into their standard practices. This shift is fueling demand for adaptable imaging solutions, fostering market expansion through improved product innovation and broader clinical application across diverse therapeutic fields and research environments, ultimately transforming the landscape of biomarker analysis and diagnostics.

Restraints in the Global Multiplex Biomarker Imaging Market

The Global Multiplex Biomarker Imaging market encounters significant challenges due to financial constraints faced by numerous research institutions and clinical laboratories, particularly those operating on tight budgets. High initial costs for advanced multiplex imaging systems, coupled with ongoing expenses related to maintenance, software licensing, and the need for specialized personnel training, create a financial obstacle. Consequently, potential purchasers frequently opt to delay or forgo investments in advanced systems to utilize traditional single-target approaches that are more budget-friendly. This cost sensitivity restricts market growth, compelling vendors to focus on affordability in order to expand their global customer base effectively.

Market Trends of the Global Multiplex Biomarker Imaging Market

The Global Multiplex Biomarker Imaging market is experiencing an upward trajectory driven by the integration of artificial intelligence and advanced imaging technologies. AI-enhanced multiplex platforms are revolutionizing assay development, allowing for swift pattern recognition across multiple targets, ultimately streamlining workflows. Machine learning algorithms optimize fluorophore selection, minimizing inefficiencies and expediting time-to-market for new diagnostics. The growing adoption of cloud-based analytics fosters collaborative efforts among research institutions, promoting standardized methodologies and shared resources. This convergence of technologies not only boosts diagnostic precision but also elevates the commercial attractiveness of multiplex imaging solutions for pharmaceutical research and precision medicine in the global healthcare landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Multiplex Biomarker Imaging Market Size by Component & CAGR (2026-2033)

• Market Overview
• Instruments
  • Imaging Systems
  • Detection Devices
• Reagents & Consumables
• Software
• Services

Global Multiplex Biomarker Imaging Market Size by Imaging Technique & CAGR (2026-2033)

• Market Overview
• Immunofluorescence (IF) Assay
• Immunohistochemistry (IHC) Assay
• Fluorescent In Situ Hybridization (FISH)
• Tissue Microarray (TMA) Assay
• Toponome Imaging System (TIS)

Global Multiplex Biomarker Imaging Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology Studies
• Drug Safety Testing
• Genetic Characterization Studies

Global Multiplex Biomarker Imaging Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Research Institutes
• Clinical Diagnostic Laboratories
• Government & Public Research Bodies

Global Multiplex Biomarker Imaging Market Size & CAGR (2026-2033)

• North America (Component, Imaging Technique, Application, End User)
  • US
  • Canada
• Europe (Component, Imaging Technique, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Component, Imaging Technique, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Component, Imaging Technique, Application, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Component, Imaging Technique, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• PerkinElmer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• US Biomax Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abcam plc (now Abcam)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Danaher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akoya Biosciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 10x Genomics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter (Danaher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioView Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hamamatsu Photonics K.K.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ventana Medical Systems (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Sigma-Aldrich)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Signaling Technology Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fluidigm Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indicell Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phenoimager (formerly Vectra PerkinElmer)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synaptic Research LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations